Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Icatibant (ATC-Code nach WHO: B06AC02)

The subject of this publication is the conclusion of non-exclusive discount agreements under § 130a para. 8 SGB V for medicines with the active substance Icatibant (WHO ATC Code: B06AC02). The contract will be concluded within the framework of an open-house model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations will not be conducted and (supply) exclusivity will not be given. It is pointed out that the quantity to be procured is unknown, as it depends on demand and the development of the number of insured persons, the prescribing behaviour of doctors and the dispensing and stocking behaviour of public pharmacies. Accordingly, minimum procurement quantities are not guaranteed. Interested pharmaceutical companies can download the participation documents from the project room of the German Award Portal (DTVP). To do this, an application for access to the project room is first required. After the applicant has been enabled by the contracting entity, the participation documents can then be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents - in particular regarding the content of the discount agreement and the discounts mentioned therein. Any complete or partial disclosure or provision of contents of the participation documents to or for third parties requires the prior written consent of the contracting entity. If participation is waived, all documents must be destroyed immediately in a data protection-compliant manner. The documents to be submitted are set out in the documents "Cover Letter" and "Explanations of the Contract Terms" stored in the project room. Communication, including the transmission of the participation documents, will be in electronic form via the tendering portal DTVP; details can be found in the aforementioned documents. Any contrary information in the contract notice is due to technical reasons and is not binding. Participation applications can be submitted for the first time by 30 April 2026. All further submission deadlines can be found in the attachment "Submission Deadlines" stored in the project room. If the deadline for submission falls on a Saturday, Sunday or public holiday throughout the country, the next working day will take its place. In the event of late receipt, the submitted applications will be considered for the next submission deadline. The discount agreement will end, regardless of the date of the contract conclusion, by 31 May 2028 at the latest. The contracting entity reserves the right to terminate the open-house procedure prematurely, in particular in the event of the conclusion of exclusive discount agreements; in this case, the discount agreements already concluded will end in accordance with the contractual provisions. According to the experience of the contracting entity, exclusive discount agreements generally come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.